List of Excipients in Branded Drug CORGARD

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
US WorldMeds LLC	CORGARD	nadolol	27505-100	CELLULOSE, MICROCRYSTALLINE
US WorldMeds LLC	CORGARD	nadolol	27505-100	FD&C BLUE NO. 2
US WorldMeds LLC	CORGARD	nadolol	27505-100	MAGNESIUM STEARATE

Corgard Excipient Strategy and Commercial Opportunities for Nadolol Tablets

Last updated: July 31, 2026

Corgard is the branded oral tablet containing nadolol, a nonselective beta-adrenergic blocker approved for hypertension and angina pectoris. Its commercial opportunity is no longer based on exclusivity around nadolol. The value lies in reliable generic manufacture, differentiated excipient systems, supply-chain resilience, and niche dosage forms that preserve bioequivalence while addressing tolerability, adherence, or patient-specific requirements.

Nadolol is an established small-molecule drug with a long commercial history. Conventional immediate-release tablets remain the principal dosage form. The original product’s patents and regulatory exclusivities have expired, leaving generic nadolol manufacturers to compete primarily on cost, quality, availability, contracting, and formulation execution.

What is Corgard and which active ingredient does it contain?

Corgard contains nadolol, a nonselective beta blocker. The product has historically been supplied as immediate-release tablets in multiple strengths, including 20 mg, 40 mg, 80 mg, and 160 mg presentations.[1]

Attribute	Corgard
Active ingredient	Nadolol
Therapeutic class	Nonselective beta-adrenergic blocker
Primary indications	Hypertension; angina pectoris
Dosage form	Immediate-release oral tablet
Administration	Once daily in the approved labeling
Regulatory pathway for generics	Abbreviated New Drug Application, or ANDA
Orange Book status	Historical NDA-listed reference product; generic listings exist
Patent position	Core product exclusivity expired
Main commercial competitors	Generic nadolol tablet manufacturers

Nadolol is administered orally and is eliminated largely through the kidneys. The prescribing information identifies renal function as a key factor in dose selection and dosing interval decisions.[1] That pharmacokinetic profile affects excipient strategy because formulation changes must not materially alter dissolution, absorption, or exposure in patients with reduced renal clearance.

What excipients are used in Corgard and generic nadolol tablets?

Corgard and generic nadolol tablets use conventional solid-dose excipients. The exact inactive-ingredient profile can vary by manufacturer, strength, manufacturing site, and approved ANDA. FDA labeling and DailyMed records should be used to verify the current inactive ingredients for a specific product.[1,2]

Typical excipient functions include:

Excipient function	Commercially relevant materials
Diluent or filler	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate
Lubricant	Magnesium stearate, sodium stearyl fumarate
Glidant	Colloidal silicon dioxide
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides
Opacifier or colorant	Titanium dioxide and approved colorants
Processing aid	Purified water or alcohol-based granulation systems, where applicable

The key formulation distinction is whether the tablet is produced by direct compression, wet granulation, or dry granulation. Each approach creates a different excipient and process risk profile.

Direct-compression strategy

Direct compression can reduce manufacturing steps and lower production cost. A high-functionality filler, such as microcrystalline cellulose or spray-dried lactose, can support tablet hardness and content uniformity. The approach is attractive for generic nadolol because the drug is available in relatively low and moderate strengths, making uniform distribution important.

The principal risks are poor flow, segregation, weight variation, and sensitivity to lubricant concentration. A direct-compression formulation should be evaluated for:

• Blend uniformity across the manufacturing hold time
• Tablet weight and content uniformity
• Tensile strength and friability
• Disintegration under relevant storage conditions
• Dissolution across pH and agitation conditions
• Scale-up sensitivity to mixing order and lubricant blending

Wet-granulation strategy

Wet granulation can improve flow and reduce segregation when the active ingredient has poor flow or when the formulation contains a high proportion of fine particles. It also allows the manufacturer to engineer granule density and tablet robustness.

The disadvantages are longer processing time, higher energy use, greater exposure to water or solvent, and more complex scale-up. Nadolol formulations should be screened for moisture sensitivity, residual moisture, and changes in dissolution after granulation and drying.

Dry-granulation strategy

Roller compaction can provide a middle path between direct compression and wet granulation. It avoids water and can improve flow and compressibility. The main development risks include ribbon density, over-compaction, fines generation, and slower disintegration.

How should manufacturers design a Corgard-compatible excipient system?

The commercial target is not to duplicate every inactive ingredient in the reference product. The target is to produce a robust, bioequivalent tablet with acceptable pharmaceutical performance and a manageable regulatory package.

A practical development sequence is:

1. Establish the reference product’s dissolution profile across multiple media.
2. Characterize the active pharmaceutical ingredient for particle size, morphology, density, flow, and moisture behavior.
3. Select a manufacturing process based on blend uniformity and tabletability.
4. Screen disintegrant type and concentration before optimizing lubricant levels.
5. Compare dissolution under discriminatory conditions rather than relying only on routine release testing.
6. Conduct pilot-scale manufacture before finalizing the control strategy.
7. Confirm that all inactive ingredients comply with FDA IID precedent and applicable USP-NF requirements.[3,4]

For low-dose strengths, content uniformity is likely to be a greater development concern than tablet hardness. For higher strengths, tablet size, swallowability, mechanical strength, and dose proportionality become more important.

What formulation patents protect Corgard or nadolol tablets?

No material, active exclusivity barrier is associated with the original nadolol tablet concept. Nadolol was approved in the United States decades ago, and the core composition-of-matter, product, and use exclusivities have expired.

The relevant intellectual-property landscape is therefore composed mainly of:

• Expired historical patents covering nadolol or its use
• Manufacturing know-how
• Supplier specifications
• Process controls
• Potentially narrow, later-filed formulation patents
• Trade secrets relating to granulation, coating, compression, and scale-up

An ANDA applicant must still assess current patent listings and certifications for the specific reference product in the FDA Orange Book. Patent absence or expiration does not eliminate regulatory obligations. The applicant must provide the applicable patent certification, including a Paragraph III certification where a listed patent remains unexpired or a Paragraph IV certification when the applicant contests validity, enforceability, or infringement.[5]

For conventional nadolol tablets, the probability of a commercially meaningful blocking patent is low. The stronger barriers are manufacturing reliability, product availability, customer qualification, and the economics of a relatively mature generic market.

When did Corgard lose exclusivity and when can generic nadolol enter?

Corgard’s core exclusivity expired long before the current generic market. Generic nadolol has been available through ANDA pathways for many years. The remaining commercial question is not first-to-file exclusivity for the historic product but whether a manufacturer can enter or expand profitably in a market with established suppliers.

Exclusivity category	Corgard and nadolol position
New chemical entity exclusivity	Expired
Core composition-of-matter protection	Expired
Original formulation protection	Expired or commercially irrelevant
Pediatric exclusivity	No current blocking significance
Biosimilar exclusivity	Not applicable
Generic market entry	Already established
Current entry constraint	Manufacturing economics, supply, quality, and contracting

Nadolol is a small molecule, not a biologic. Biosimilar pathways and biologic interchangeability rules do not apply. Competition proceeds through generic-drug approval and state substitution rules rather than biosimilar approval.

What is the Orange Book status of Corgard and nadolol?

The Orange Book identifies approved drug products, therapeutic-equivalence evaluations, and applicable patent and exclusivity information. For commercial diligence, the relevant questions are:

• Which NDA is the reference listed drug?
• Is the Corgard NDA currently marketed, discontinued, or listed as a reference product?
• Which nadolol ANDAs have active approval?
• Which strengths and dosage forms have TE codes?
• Are any patents or pediatric exclusivities listed?
• Are there approved products from multiple manufacturers?

The Orange Book must be checked by strength and dosage form because a company may have approval for one strength but not the full Corgard portfolio.[5] DailyMed should then be used to compare current labeling, inactive ingredients, package sizes, and manufacturer-specific product information.[2]

What commercial opportunities exist for Corgard excipient innovation?

Lactose-free nadolol tablets

A lactose-free formulation can address patients with lactose intolerance and provide a differentiated product specification for institutional buyers. The commercial value is limited unless the formulation is supported by reliable supply, clear labeling, and a contracting strategy.

Mannitol, microcrystalline cellulose, dibasic calcium phosphate, and starch-based systems are possible alternatives, subject to compatibility, compression, dissolution, and regulatory review.

Low-moisture and tropical-stability formulations

A formulation optimized for humidity resistance can reduce packaging requirements and improve distribution in markets with challenging storage conditions. Candidate approaches include:

• Moisture-resistant film coating
• High-barrier blister packaging
• Desiccant-equipped bottles
• Reduced hygroscopic excipient load
• Tighter residual-moisture controls

The commercial advantage is strongest where supply interruptions or climate-related degradation create a quality or availability problem.

Smaller or easier-to-swallow tablets

Nadolol tablets can be optimized for tablet volume, shape, coating, and surface characteristics. Smaller tablets may improve adherence, although dose strength and excipient loading constrain the achievable size.

A manufacturer should avoid unnecessary size reduction that increases compression force, slows disintegration, or creates capping and lamination.

Color-coded strength architecture

A consistent color and imprint system across 20 mg, 40 mg, 80 mg, and 160 mg strengths can reduce medication errors and support pharmacy operations. This is a product-design opportunity rather than a strong patent opportunity.

The design must remain distinct from other marketed products and comply with imprinting, labeling, and colorant requirements.

Pediatric and geriatric presentations

Nadolol is not principally commercialized as a pediatric liquid product in the same way as many high-volume cardiovascular medicines. A ready-to-use suspension, dispersible tablet, or extemporaneous-compounding platform could address selected patients, but it would require substantial stability, dose-uniformity, preservative, container-closure, and palatability work.

A liquid product may also create new risks, including sedimentation, microbial control, dosing-device accuracy, and altered exposure. The opportunity is more specialized than a conventional tablet launch.

Unit-dose and adherence packaging

Calendar blister packs, unit-dose hospital packaging, and pharmacy-ready bottles can create procurement value without changing the active formulation. This strategy is particularly relevant for chronic hypertension treatment, where refill continuity and medication identification influence pharmacy purchasing.

How strong is the patent estate for Corgard excipient innovations?

The patent estate is weak for routine excipient substitutions. A formulation patent would need to establish a credible technical advantage, such as:

• A defined dissolution profile across a broad storage range
• Improved content uniformity at a low dose
• Reduced impurity formation
• Enhanced stability under high humidity
• A specific suspension with demonstrated physical and chemical stability
• A manufacturing process that produces a reproducible, non-obvious result

Claims directed only to replacing lactose with mannitol, or magnesium stearate with another lubricant, are vulnerable to obviousness challenges unless supported by unexpected performance data.

Trade-secret protection may be more practical for process parameters, blending order, granulation endpoint, compression settings, and coating conditions. A company seeking defensible differentiation should combine narrowly drafted formulation claims with process controls, supplier qualification, and regulatory execution.

Which companies are challenging or competing with Corgard?

Generic nadolol competition has historically included multiple ANDA holders and contract manufacturers. The precise active supplier set changes because approvals, marketing status, manufacturing sites, and product availability change over time.

The competitive landscape should be assessed using:

• FDA Orange Book ANDA listings
• FDA Drug Shortages database
• DailyMed manufacturer records
• National Drug Code listings
• Medicaid and commercial formulary data
• Wholesale acquisition cost and pharmacy acquisition data
• Procurement contracts and wholesaler availability

The strongest opportunity may arise when the market has few active suppliers despite multiple historical approvals. An approved ANDA that is not commercially supplied does not create effective competition.

What generic launch risks exist for a new nadolol product?

A new nadolol launch faces several practical risks:

Risk	Commercial effect	Mitigation
Low market size	Limited return on development spending	Use shared manufacturing and portfolio economics
Price compression	Erodes gross margin	Secure institutional contracts and supply differentiation
API concentration	Creates shortage exposure	Qualify alternate suppliers
Dissolution mismatch	Delays ANDA approval or creates BE risk	Use early reference-product profiling
Tablet segregation	Causes content-uniformity failures	Optimize particle-size distribution and process controls
Packaging failure	Creates stability or recall risk	Use high-barrier packaging where justified
Single-site dependence	Increases interruption risk	Dual-source critical operations
Formulary exclusion	Limits volume	Target underserved channels and regional buyers

The most credible launch strategy is a low-complexity, high-reliability tablet supported by multiple strengths and dependable supply. A premium price for excipient differentiation alone is unlikely in a mature generic market.

What licensing and partnering opportunities exist?

Nadolol licensing opportunities are more likely to involve manufacturing, geographic rights, or portfolio aggregation than molecule-level intellectual property.

Potential structures include:

• Technology transfer of an approved ANDA
• Contract manufacturing and supply agreements
• Regional commercialization rights
• Co-development of a liquid or dispersible dosage form
• Acquisition of an under-supplied generic portfolio
• Dual-source supply agreements with hospitals or wholesalers
• Licensing of a packaging or adherence platform

A partner should evaluate transferability of the formulation, process validation status, stability data, DMF support, inspection history, and manufacturing-site capacity. The presence of an approved product does not guarantee that a technology transfer will preserve dissolution and content-uniformity performance at commercial scale.

How does Corgard compare with other beta-blocker opportunities?

Nadolol has a smaller market opportunity than high-volume generic beta blockers such as metoprolol, carvedilol, and propranolol. Its advantages are established clinical use, simple oral dosage forms, and no biosimilar complexity. Its disadvantages are mature competition, limited patent leverage, and constrained pricing power.

Product	Commercial profile	Excipient opportunity
Nadolol/Corgard	Mature, niche generic	Stability, swallowability, packaging, supply reliability
Metoprolol	Larger and more formulation-sensitive market	Extended-release technology and robust dissolution control
Carvedilol	Broad generic demand	Immediate-release and controlled-release differentiation
Propranolol	Broad indications and dosage forms	Liquid, pediatric, and modified-release platforms
Bisoprolol	Established chronic-use market	Tablet size, dose flexibility, and supply economics

Nadolol is best treated as a portfolio product or supply-resilience opportunity rather than a standalone premium formulation program.

Key Takeaways

• Corgard contains nadolol and is primarily an immediate-release tablet product.
• Core Corgard and nadolol exclusivities have expired, and generic entry is established.
• Excipient differentiation should focus on manufacturability, stability, tablet size, lactose-free positioning, and packaging.
• Routine excipient substitutions have limited patent strength without unexpected technical results.
• Nadolol is a small molecule, so biosimilar risk is not relevant.
• The Orange Book, DailyMed, and FDA drug-shortage records are the key sources for current product, manufacturer, and regulatory status.
• Commercial value depends more on supply reliability and portfolio economics than on premium pricing.
• Liquid, dispersible, pediatric, and adherence-oriented products offer the clearest formulation-led opportunities, but each requires additional stability and regulatory work.

FAQs About Corgard Excipients and Nadolol Commercialization

Can a company launch lactose-free nadolol without a new patent?

Yes. A lactose-free formulation can generally be pursued through an ANDA if it meets applicable quality and bioequivalence requirements. The formulation itself does not need to duplicate the reference product’s excipient profile.

Is nadolol a good candidate for an extended-release formulation?

The opportunity is technically possible but commercially uncertain. Nadolol is already administered once daily in the approved product, which reduces the adherence benefit available from extended release. Development would require evidence of a meaningful clinical or pharmacokinetic advantage.

Are Corgard excipients protected by trade secrets?

Specific manufacturing parameters, blending order, granulation endpoint, compression settings, and coating controls may be treated as trade secrets. Routine excipient identities are generally disclosed in product labeling or regulatory records.

Can nadolol be developed as an oral suspension?

Yes, but the product would require stability, dose-uniformity, sedimentation, preservative, container-closure, and dosing-device studies. The regulatory and commercial burden is higher than for a conventional tablet.

What is the highest-value formulation opportunity for generic nadolol?

A robust, moisture-resistant, lactose-free tablet supplied across major strengths is the most practical opportunity. A liquid or dispersible product may offer greater differentiation but carries materially higher development and commercialization risk.

References

1. U.S. Food and Drug Administration. (2017). Corgard (nadolol) tablets prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Nadolol and Corgard product labeling.
3. U.S. Food and Drug Administration. (2023). Inactive Ingredient Database.
4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.